Pangaea Data enters AI collaboration with Alexion to help improve detection of HPP in adults
London (UK) and South San Francisco, CA (USA), June 9th, 2025: Pangaea Data Limited (“Pangaea Data”), provider of a novel Artificial Intelligence (AI)-driven platform to improve detection of hard-to-diagnose conditions in a privacy-preserving and scalable manner, has entered into a collaboration agreement with Alexion, AstraZeneca Rare Disease (“Alexion”). This collaboration aims to develop, clinically validate, and obtain regulatory approval for an Artificial Intelligence Clinical Decision Support System (AI-CDSS) designed to improve detection of Hypophosphatasia (HPP) in adults. As part of this collaboration, Alexion will provide the funding for the development of the AI-CDSS.
HPP is a rare, inherited disorder that results from Alkaline phosphatase (ALP) deficiency, or low ALP, which is associated with reduced bone mineralisation, impaired energy metabolism, and compromised neurotransmitter function [1,2.]. The manifestations of HPP can be wide-ranging, and the disease often remains undiagnosed or misdiagnosed due to its diverse and non-specific symptoms. By leveraging AI and clinical guidelines, the AI-CDSS developed by Pangaea Data in collaboration with Alexion will seek to improve the detection of HPP in adults based on information from electronic health records (EHRs). With improved detection, adults living with HPP could receive a timelier diagnosis and clinical intervention, ultimately achieving better health outcomes.
Dr. Vibhor Gupta, Founder and CEO, Pangaea Data said: “We are excited to partner with Alexion. The scalable application of Pangaea’s AI platform to detect hard-to-diagnose conditions, like HPP in adults, has the potential to benefit both patients and clinicians by enabling accurate and timely diagnosis thereby unlocking the full potential of precision medicine.”
“Adults living with a rare disease such as HPP often wait years to receive an accurate diagnosis because of the complex nature, varied symptoms and limited awareness of the condition, a journey that is inherently inequitable,” said Seng H. Cheng, Senior Vice President, Head of Research and Product Development, Alexion. “We are committed to supporting potential solutions to help enable accurate and timely diagnoses which can make a critical impact in the ability to treat patients, and we look forward to advancing this collaboration with Pangaea Data.”
———— ENDS ————
Media Enquiries: pr@pangaeadata.ai
About Pangaea Data: www.pangaeadata.ai
Pangaea Data provides an AI platform that is configured on clinical guidelines to find untreated (undiagnosed, misdiagnosed, miscoded, at-risk, uncontrolled) and under-treated patients with hard-to-diagnose conditions for screening and treatment at the point of care. These patients may otherwise be missed, despite information available in their health records, due to treatment for other conditions or administrative reasons. Pangaea’s platform is designed to be deployed behind the healthcare organization’s firewall, without moving data, facilitating privacy compliance. Furthermore, the platform is designed to seamlessly integrate with existing EHR systems, avoiding disruption to existing clinical or IT workflows. Pangaea Data’s founders, Dr. Vibhor Gupta and Prof. Yike Guo, have over 20 years of academic and industry experience. Their advisors and investors include industry veterans, such as Lord David Prior (Former Chairman, NHS England) and Mr. Andy Palmer (Former Head of Systems Integration, Novartis).
